Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial

Summary Background The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer's disease (AD). Here we report its efficacy in patients with severe AD. Methods Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (m...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lancet neurology 2009, Vol.8 (1), p.39-47
Hauptverfasser:	Burns, Alistair, MD, Bernabei, Roberto, MD, Bullock, Roger, MD, Jentoft, Alfonso J Cruz, MD, Frölich, Lutz, MD, Hock, Christoph, MD, Raivio, Minna, MD, Triau, Eric, MD, Vandewoude, Maurits, MD, Wimo, Anders, MD, Came, Elizabeth, PhD, Van Baelen, Bart, MSc, Hammond, Gerry L, BSc, van Oene, Joop C, PhD, Schwalen, Susanne, MD
Format:	Artikel
Sprache:	eng
Schlagworte:	Activities of Daily Living Aged, 80 and over Alzheimer Disease - drug therapy Alzheimer Disease - mortality Alzheimer Disease - psychology Alzheimer's disease Caregivers Cerebrovascular disease Cognition - physiology Cognitive ability Consent Dementia Double-Blind Method Electrocardiography - drug effects Female Galantamine - adverse effects Galantamine - therapeutic use Humans Male Metabolism Neurology Neuropsychological Tests Nootropic Agents - adverse effects Nootropic Agents - therapeutic use Nursing homes Vitamin deficiency
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!